Abstract:Abstract The mechanism of action of many cancer drugs at the subcellular level remains unknown. Yet, this knowledge could be critical in driving structure-activity-relationship studies to improve their efficacy and selectivity. To gain a deeper understanding of the mechanisms governing the action of anticancer drugs within cells, we are developing an innovative methodology to visualize drug interactions. Carbon dots (CDs) are carbon-based nanoparticles, distinguished not only by their remarkable optical properties but also by their minimal cytotoxicity, rendering them highly suitable for bioimaging applications. We recently found that amine-passivated CDs with a negative surface charge and amphiphilic properties were enriched in the cytosol of cultured human cells. These CDs emit fluorescence in the blue spectra with high quantum yields and are not cytotoxic. Importantly, their surface is decorated with amine functional groups that can be used for coupling to polyethylene glycol to create a linker that can be covalently attached to drugs of interest. First, we are covalently linking amine-passivated CDs to Doxorubicin (Dox), a well-known anti-cancer drug that intercalates DNA and also has fluorescence properties that differ from the CDs. This will permit us to monitor and validate the conjugation of Dox to CDs, their cellular uptake and localization. The next step will be to use this approach to reveal the cellular mechanism of action of novel anticancer drugs. Specifically, our group has rationally designed thienoisoquinoline compounds with selectivity and high efficacy for triple negative breast cancer cells. In vitro they disrupt microtubule polymerization in the nanomolar range. However, in cells they cause mitotic arrest and spindle phenotypes that are distinct from colchicine, another microtubule-targeting drug. Our approach will reveal if these compounds target the centrosomes and/or microtubules and if this varies with cell types. This innovative approach could yield profound insights into the intracellular mechanisms of anticancer drugs to facilitate structure-activity-relationship studies, to improve their efficacy and selectivity for drug development. Citation Format: Adryanne Clermont-Paquette. Fluorescent carbon dots: A novel bioimaging tool to reveal the mechanism of action of anticancer drugs in cells [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 494.

Intracellular Metabolism and Action of an Antitumor Nucleoside, 2′-C-cyano-2′-deoxy-1-β-d-arabinofuranosylcytosine (CNDAC)

Action of (E)-2 '-Deoxy-2 '-(Fluoromethylene)cytidine on Dna Metabolism: Incorporation, Excision, and Cellular Response

Simultaneous quantitative determination of 5-aza-2'-deoxycytidine genomic incorporation and DNA demethylation by liquid chromatography tandem mass spectrometry as exposure-response measures of nucleoside analog DNA methyltransferase inhibitors.

Nucleoside conjugates. 7. Synthesis and antitumor activity of 1-beta-D-arabinofuranosylcytosine conjugates of ether lipids

FNC (4′-azido-2′-deoxy-2′-fluoro(arbino)cytidine) as an Effective Therapeutic Agent for NHL: ROS Generation, Cell Cycle Arrest, and Mitochondrial-Mediated Apoptosis

Preclinical Characteristics of Cytarabine, Gemcitabine, Fludarabine and Cladribine: Relevance for Clinical Studies

Butterfly Effect in Cytarabine: Combined NMR-NQR Experiment, Solid-State Computational Modeling, Quantitative Structure-Property Relationships and Molecular Docking Study

Crystallographic and molecular mechanics calculations on the anti-tumor drugs N-[(2-dimethylamino)ethyl]-and N-[(2-dimethyl-amino)butyl]-9-aminoacridine-4-carboxamides and their dications: implications for models of DNA-binding

Design, Synthesis, and Activity Evaluation of Novel Acyclic Nucleosides as Potential Anticancer Agents <i>In Vitro</i> and <i>In Vivo</i>

Novel Synthetic 2-Amino-10-(3,5-dimethoxy)benzyl-9(10h)-acridinone Derivatives As Potent DNA-binding Antiproliferative Agents.

Anthracyclines React with Apurinic/Apyrimidinic Sites in DNA

Investigations on the mechanism of action of the novel antitumor agents 2-benzothiazolyl, 2-benzoxazolyl, and 2-benzimidazolyl hydrazones derived from 2-acetylpyridine

Abstract 494: Fluorescent carbon dots: A novel bioimaging tool to reveal the mechanism of action of anticancer drugs in cells

Design, Synthesis, and Activity Evaluation of Novel Acyclic Nucleosides as Potential Anticancer Agents In Vitro and In Vivo

Studies on the mechanism of action of tiazofurin (2-beta-D-ribofuranosylthiazole-4-carboxamide). VI. Biochemical and pharmacological studies on the degradation of thiazole-4-carboxamide adenine dinucleotide (TAD)

Novel N-phenyl Dichloroacetamide Derivatives As Anticancer Reagents: Design, Synthesis and Biological Evaluation.

Recent Advances in the Chemical Synthesis and Evaluation of Anticancer Nucleoside Analogues

Chemical decomposition of 5-aza-2'-deoxycytidine (Decitabine): kinetic analyses and identification of products by NMR, HPLC, and mass spectrometry

Synthesis, characterization, in silico and in vitro assessment of 2-aminopyridine nicotinamide cocrystal as a new agent for breast cancer therapy

Purine nucleoside analogues for the treatment of hematological malignancies: pharmacology and clinical applications

Fludarabine Inhibits DNA Replication: A Rationale for Its Use in the Treatment of Acute Leukemias